{"id":"liraglutide-pen-injector-saxenda","safety":{"commonSideEffects":[{"rate":"25–40%","effect":"Nausea"},{"rate":"10–20%","effect":"Vomiting"},{"rate":"15–25%","effect":"Diarrhea"},{"rate":"10–20%","effect":"Constipation"},{"rate":"10–15%","effect":"Headache"},{"rate":"5–10%","effect":"Injection site reactions"},{"rate":"<1%","effect":"Pancreatitis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone that regulates blood glucose and appetite. By binding to GLP-1 receptors in the hypothalamus and other brain regions, it decreases hunger signals and increases feelings of fullness. At higher doses (as in Saxenda), the weight-loss effect predominates over glucose control.","oneSentence":"Liraglutide activates GLP-1 receptors in the brain and pancreas to reduce appetite, increase satiety, and promote weight loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:41.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Saxenda","Victoza","Liraglutide 3mg"],"phase":"marketed","status":"active","brandName":"Liraglutide Pen Injector [Saxenda]","genericName":"Liraglutide Pen Injector [Saxenda]","companyName":"University College, London","companyId":"university-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liraglutide activates GLP-1 receptors in the brain and pancreas to reduce appetite, increase satiety, and promote weight loss. Used for Chronic weight management in adults with obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}